New COVID variant of concern before 2027?
Overestimating short-term impact (Amara's Law). AI estimates 11% vs market's 14%, suggesting the market overprices this outcome.
Alpha Opportunity
Alpha Thesis
A new COVID variant of concern before 2027 is 12%. WHO hasn't designated a new VOC since the early Omicron sub-variants (de-escalated in Mar 2023). Current variants (XFG/Stratus, NB.1.8.1) are only 'Variants Under Monitoring'. New VOC requires significant evidence of increased severity/transmissibility beyond current strains. Population immunity is high.
📐Key Metrics
Key Findings
- WHO has NOT designated a new VOC since de-escalating BA.2/BA.4/BA.5 in March 2023.
- Current dominant variants: XFG/Stratus (29% US), NB.1.8.1 (21% US). Both are VUMs.
- High population immunity from vaccination + infection reduces VOC criteria.
- For new VOC designation: variant must show significantly increased severity/transmissibility.
- COVID risk level remains 'high' per WHO but health impact declining.
Full Research Report
Unlock the complete analysis including probability assessment, Bayesian calculations, resolution rigor analysis, and strategic positioning recommendations across 5+ dimensions.
Alpha Quality Factors
Criteria that determine how exploitable this mispricing is
Human Bias Detected
Cognitive biases creating this alpha opportunity
Markets at extreme ends tend to be miscalibrated — people overestimate tiny risks or underestimate near-certainties.
Compare Markets
Searching Polymarket, Kalshi, Manifold & Metaculus…
Market Data
Position Sizing
Kelly Criterion (per $1,000 bankroll)